In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells

Deepak Assudani, Hyun Il Cho, Nicholas DeVito, Norma Bradley, Esteban Celis

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Significant efforts are being devoted toward the development of effective therapeutic vaccines against cancer. Specifically, well-characterized subunit vaccines, which are designed to generate antitumor cytotoxic CD8 T-cell responses. Because CD4 T cells participate at various stages of CD8 T-cell responses, it is important to study the role of CD4 T cells in the induction and persistence of antitumor CD8 T-cell responses by these vaccines. Recent evidence points to the requirement of CD4 T cells for the long-term persistence of memory CD8 T cells, which in the case of cancer immunotherapy would be critical for the prevention of tumor recurrences. The purpose of the present study was to assess whether CD4 T cells are necessary for the generation and maintenance of antigen-specific CD8 T cells induced by subunit (peptide or DNA) vaccines. We have used a vaccination strategy that combines synthetic peptides representing CD8 T-cell epitopes, a costimulatory anti-CD40 antibody and a Toll-like receptor agonist (TriVax) to generate large numbers of antigen-specific CD8 T-cell responses. Our results show that the rate of decline (clonal contraction) of the antigen-specific CD8 T cells and their functional state is not affected by the presence or absence of CD4 T cells throughout the immune response generated by TriVax. We believe that these results bear importance for the design of effective vaccination strategies against cancer.

Original languageEnglish (US)
Pages (from-to)9892-9899
Number of pages8
JournalCancer Research
Volume68
Issue number23
DOIs
StatePublished - Dec 1 2008

Fingerprint

Subunit Vaccines
T-Lymphocytes
CD8 Antigens
Vaccination
Neoplasms
Peptides
Cancer Vaccines
DNA Vaccines
T-Lymphocyte Epitopes
Long-Term Memory
Toll-Like Receptors
Immunotherapy
Anti-Idiotypic Antibodies
Vaccines
Maintenance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. / Assudani, Deepak; Cho, Hyun Il; DeVito, Nicholas; Bradley, Norma; Celis, Esteban.

In: Cancer Research, Vol. 68, No. 23, 01.12.2008, p. 9892-9899.

Research output: Contribution to journalArticle

Assudani, Deepak ; Cho, Hyun Il ; DeVito, Nicholas ; Bradley, Norma ; Celis, Esteban. / In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells. In: Cancer Research. 2008 ; Vol. 68, No. 23. pp. 9892-9899.
@article{76e944b6a2d44711bd0b6ba10d896f80,
title = "In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells",
abstract = "Significant efforts are being devoted toward the development of effective therapeutic vaccines against cancer. Specifically, well-characterized subunit vaccines, which are designed to generate antitumor cytotoxic CD8 T-cell responses. Because CD4 T cells participate at various stages of CD8 T-cell responses, it is important to study the role of CD4 T cells in the induction and persistence of antitumor CD8 T-cell responses by these vaccines. Recent evidence points to the requirement of CD4 T cells for the long-term persistence of memory CD8 T cells, which in the case of cancer immunotherapy would be critical for the prevention of tumor recurrences. The purpose of the present study was to assess whether CD4 T cells are necessary for the generation and maintenance of antigen-specific CD8 T cells induced by subunit (peptide or DNA) vaccines. We have used a vaccination strategy that combines synthetic peptides representing CD8 T-cell epitopes, a costimulatory anti-CD40 antibody and a Toll-like receptor agonist (TriVax) to generate large numbers of antigen-specific CD8 T-cell responses. Our results show that the rate of decline (clonal contraction) of the antigen-specific CD8 T cells and their functional state is not affected by the presence or absence of CD4 T cells throughout the immune response generated by TriVax. We believe that these results bear importance for the design of effective vaccination strategies against cancer.",
author = "Deepak Assudani and Cho, {Hyun Il} and Nicholas DeVito and Norma Bradley and Esteban Celis",
year = "2008",
month = "12",
day = "1",
doi = "10.1158/0008-5472.CAN-08-3134",
language = "English (US)",
volume = "68",
pages = "9892--9899",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - In vivo expansion, persistence, and function of peptide vaccine-induced CD8 T cells occur independently of CD4 T cells

AU - Assudani, Deepak

AU - Cho, Hyun Il

AU - DeVito, Nicholas

AU - Bradley, Norma

AU - Celis, Esteban

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Significant efforts are being devoted toward the development of effective therapeutic vaccines against cancer. Specifically, well-characterized subunit vaccines, which are designed to generate antitumor cytotoxic CD8 T-cell responses. Because CD4 T cells participate at various stages of CD8 T-cell responses, it is important to study the role of CD4 T cells in the induction and persistence of antitumor CD8 T-cell responses by these vaccines. Recent evidence points to the requirement of CD4 T cells for the long-term persistence of memory CD8 T cells, which in the case of cancer immunotherapy would be critical for the prevention of tumor recurrences. The purpose of the present study was to assess whether CD4 T cells are necessary for the generation and maintenance of antigen-specific CD8 T cells induced by subunit (peptide or DNA) vaccines. We have used a vaccination strategy that combines synthetic peptides representing CD8 T-cell epitopes, a costimulatory anti-CD40 antibody and a Toll-like receptor agonist (TriVax) to generate large numbers of antigen-specific CD8 T-cell responses. Our results show that the rate of decline (clonal contraction) of the antigen-specific CD8 T cells and their functional state is not affected by the presence or absence of CD4 T cells throughout the immune response generated by TriVax. We believe that these results bear importance for the design of effective vaccination strategies against cancer.

AB - Significant efforts are being devoted toward the development of effective therapeutic vaccines against cancer. Specifically, well-characterized subunit vaccines, which are designed to generate antitumor cytotoxic CD8 T-cell responses. Because CD4 T cells participate at various stages of CD8 T-cell responses, it is important to study the role of CD4 T cells in the induction and persistence of antitumor CD8 T-cell responses by these vaccines. Recent evidence points to the requirement of CD4 T cells for the long-term persistence of memory CD8 T cells, which in the case of cancer immunotherapy would be critical for the prevention of tumor recurrences. The purpose of the present study was to assess whether CD4 T cells are necessary for the generation and maintenance of antigen-specific CD8 T cells induced by subunit (peptide or DNA) vaccines. We have used a vaccination strategy that combines synthetic peptides representing CD8 T-cell epitopes, a costimulatory anti-CD40 antibody and a Toll-like receptor agonist (TriVax) to generate large numbers of antigen-specific CD8 T-cell responses. Our results show that the rate of decline (clonal contraction) of the antigen-specific CD8 T cells and their functional state is not affected by the presence or absence of CD4 T cells throughout the immune response generated by TriVax. We believe that these results bear importance for the design of effective vaccination strategies against cancer.

UR - http://www.scopus.com/inward/record.url?scp=57149086082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57149086082&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-3134

DO - 10.1158/0008-5472.CAN-08-3134

M3 - Article

C2 - 19047170

AN - SCOPUS:57149086082

VL - 68

SP - 9892

EP - 9899

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 23

ER -